Search

Your search keyword '"Krämer, Alwin"' showing total 454 results
Start Over Author "Krämer, Alwin" Search Limiters Available in Library Collection
454 results on '"Krämer, Alwin"'

1. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Author

Pouyiourou, Maria, Kraft, Bianca N., Wohlfromm, Timothy, Stahl, Michael, Kubuschok, Boris, Löffler, Harald, Hacker, Ulrich T., Hübner, Gerdt, Weiss, Lena, Bitzer, Michael, Ernst, Thomas, Schütt, Philipp, Hielscher, Thomas, Delorme, Stefan, Kirchner, Martina, Kazdal, Daniel, Ball, Markus, Kluck, Klaus, Stenzinger, Albrecht, Bochtler, Tilmann, and Krämer, Alwin

Published
2023
Full Text
View/download PDF

2. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

Author

Homan, Claire C., Drazer, Michael W., Yu, Kai, Lawrence, David M., Feng, Jinghua, Arriola-Martinez, Luis, Pozsgai, Matthew J., McNeely, Kelsey E., Ha, Thuong, Venugopal, Parvathy, Arts, Peer, King-Smith, Sarah L., Cheah, Jesse, Armstrong, Mark, Wang, Paul, Bödör, Csaba, Cantor, Alan B., Cazzola, Mario, Degelman, Erin, DiNardo, Courtney D., Duployez, Nicolas, Favier, Remi, Fröhling, Stefan, Rio-Machin, Ana, Klco, Jeffery M., Krämer, Alwin, Kurokawa, Mineo, Lee, Joanne, Malcovati, Luca, Morgan, Neil V., Natsoulis, Georges, Owen, Carolyn, Patel, Keyur P., Preudhomme, Claude, Raslova, Hana, Rienhoff, Hugh, Ripperger, Tim, Schulte, Rachael, Tawana, Kiran, Velloso, Elvira, Yan, Benedict, Kim, Erika, Sood, Raman, Hsu, Amy P., Holland, Steven M., Phillips, Kerry, Poplawski, Nicola K., Babic, Milena, Wei, Andrew H., Forsyth, Cecily, Mar Fan, Helen, Lewis, Ian D., Cooney, Julian, Susman, Rachel, Fox, Lucy C., Blombery, Piers, Singhal, Deepak, Hiwase, Devendra, Phipson, Belinda, Schreiber, Andreas W., Hahn, Christopher N., Scott, Hamish S., Liu, Paul, Godley, Lucy A., and Brown, Anna L.

Published
2023
Full Text
View/download PDF

3. Synthetic patches, real images: screening for centrosome aberrations in EM images of human cancer cells

Author

Lukoyanov, Artem, Haberbosch, Isabella, Pape, Constantin, Kraemer, Alwin, Schwab, Yannick, and Kreshuk, Anna

Subjects
Computer Science - Computer Vision and Pattern Recognition
Abstract

Recent advances in high-throughput electron microscopy imaging enable detailed study of centrosome aberrations in cancer cells. While the image acquisition in such pipelines is automated, manual detection of centrioles is still necessary to select cells for re-imaging at higher magnification. In this contribution we propose an algorithm which performs this step automatically and with high accuracy. From the image labels produced by human experts and a 3D model of a centriole we construct an additional training set with patch-level labels. A two-level DenseNet is trained on the hybrid training data with synthetic patches and real images, achieving much better results on real patient data than training only at the image-level. The code can be found at https://github.com/kreshuklab/centriole_detection., Comment: Accepted at MICCAI 2019

Published
2019

4. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Author

Kunadt, Desiree, Stasik, Sebastian, Metzeler, Klaus H., Röllig, Christoph, Schliemann, Christoph, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Scholl, Sebastian, Hilgendorf, Inken, Brümmendorf, Tim H., Jost, Edgar, Steffen, Björn, Bug, Gesine, Einsele, Hermann, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Wörmann, Bernhard, Kramer, Michael, Sockel, Katja, Egger-Heidrich, Katharina, Herold, Tobias, Ehninger, Gerhard, Burchert, Andreas, Platzbecker, Uwe, Berdel, Wolfgang E., Müller-Tidow, Carsten, Hiddemann, Wolfgang, Serve, Hubert, Stelljes, Matthias, Baldus, Claudia D., Neubauer, Andreas, Schetelig, Johannes, Thiede, Christian, Bornhäuser, Martin, Middeke, Jan M., and Stölzel, Friedrich

Published
2022
Full Text
View/download PDF

5. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Author

Eckardt, Jan-Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Published
2022
Full Text
View/download PDF

7. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Author

Middeke, Jan M., Metzeler, Klaus H., Röllig, Christoph, Krämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Desiree, Wörmann, Bernhard, Sockel, Katja, von Bonin, Malte, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia D., Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, and Thiede, Christian

Published
2022
Full Text
View/download PDF

8. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Author

Taube, Franziska, Georgi, Julia Annabell, Kramer, Michael, Stasik, Sebastian, Middeke, Jan Moritz, Röllig, Christoph, Krug, Utz, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Petzold, Andreas, Mulet-Lazaro, Roger, Valk, Peter J.M., Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Herold, Sylvia, Stölzel, Friedrich, Sockel, Katja, von Bonin, Malte, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, and Thiede, Christian

Published
2022
Full Text
View/download PDF

9. Prediction of acute myeloid leukaemia risk in healthy individuals.

Author

Abelson, Sagi, Collord, Grace, Ng, Stanley WK, Weissbrod, Omer, Mendelson Cohen, Netta, Niemeyer, Elisabeth, Barda, Noam, Zuzarte, Philip C, Heisler, Lawrence, Sundaravadanam, Yogi, Luben, Robert, Hayat, Shabina, Wang, Ting Ting, Zhao, Zhen, Cirlan, Iulia, Pugh, Trevor J, Soave, David, Ng, Karen, Latimer, Calli, Hardy, Claire, Raine, Keiran, Jones, David, Hoult, Diana, Britten, Abigail, McPherson, John D, Johansson, Mattias, Mbabaali, Faridah, Eagles, Jenna, Miller, Jessica K, Pasternack, Danielle, Timms, Lee, Krzyzanowski, Paul, Awadalla, Philip, Costa, Rui, Segal, Eran, Bratman, Scott V, Beer, Philip, Behjati, Sam, Martincorena, Inigo, Wang, Jean CY, Bowles, Kristian M, Quirós, J Ramón, Karakatsani, Anna, La Vecchia, Carlo, Trichopoulou, Antonia, Salamanca-Fernández, Elena, Huerta, José M, Barricarte, Aurelio, Travis, Ruth C, Tumino, Rosario, Masala, Giovanna, Boeing, Heiner, Panico, Salvatore, Kaaks, Rudolf, Krämer, Alwin, Sieri, Sabina, Riboli, Elio, Vineis, Paolo, Foll, Matthieu, McKay, James, Polidoro, Silvia, Sala, Núria, Khaw, Kay-Tee, Vermeulen, Roel, Campbell, Peter J, Papaemmanuil, Elli, Minden, Mark D, Tanay, Amos, Balicer, Ran D, Wareham, Nicholas J, Gerstung, Moritz, Dick, John E, Brennan, Paul, Vassiliou, George S, and Shlush, Liran I

Subjects
Humans, Disease Progression, Genetic Predisposition to Disease, Prevalence, Risk Assessment, Age Factors, Mutagenesis, Mutation, Models, Genetic, Adult, Aged, Middle Aged, Health, Female, Male, Leukemia, Myeloid, Acute, Electronic Health Records, Models, Genetic, Leukemia, Myeloid, Acute, General Science & Technology
Abstract

The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure1. The onset of such de novo AML cases is typically preceded by the accumulation of somatic mutations in preleukaemic haematopoietic stem and progenitor cells (HSPCs) that undergo clonal expansion2,3. However, recurrent AML mutations also accumulate in HSPCs during ageing of healthy individuals who do not develop AML, a phenomenon referred to as age-related clonal haematopoiesis (ARCH)4-8. Here we use deep sequencing to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH. We analysed peripheral blood cells from 95 individuals that were obtained on average 6.3 years before AML diagnosis (pre-AML group), together with 414 unselected age- and gender-matched individuals (control group). Pre-AML cases were distinct from controls and had more mutations per sample, higher variant allele frequencies, indicating greater clonal expansion, and showed enrichment of mutations in specific genes. Genetic parameters were used to derive a model that accurately predicted AML-free survival; this model was validated in an independent cohort of 29 pre-AML cases and 262 controls. Because AML is rare, we also developed an AML predictive model using a large electronic health record database that identified individuals at greater risk. Collectively our findings provide proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation. This could in future enable earlier detection and monitoring, and may help to inform intervention.

Published
2018

10. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Author

Cortes, Jorge, Perl, Alexander E, Döhner, Hartmut, Kantarjian, Hagop, Martinelli, Giovanni, Kovacsovics, Tibor, Rousselot, Philippe, Steffen, Björn, Dombret, Hervé, Estey, Elihu, Strickland, Stephen, Altman, Jessica K, Baldus, Claudia D, Burnett, Alan, Krämer, Alwin, Russell, Nigel, Shah, Neil P, Smith, Catherine C, Wang, Eunice S, Ifrah, Norbert, Gammon, Guy, Trone, Denise, Lazzaretto, Deborah, and Levis, Mark

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Hematology, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Administration, Oral, Adult, Aged, Benzothiazoles, Canada, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Europe, Female, Humans, Internationality, Leukemia, Myeloid, Acute, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Phenylurea Compounds, Prognosis, Survival Rate, Treatment Outcome, United States, Young Adult, fms-Like Tyrosine Kinase 3, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundOld age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia.MethodsWe did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission + complete remission with incomplete platelet recovery + complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed.FindingsBetween Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia's formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [

Published
2018

11. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., and Thiede, Christian

Published
2021
Full Text
View/download PDF

12. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial

Author

Ganguly, Siddhartha, Cortes, Jorge E., Krämer, Alwin, Levis, Mark J., Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Arunachalam, Meena, Santos, Cedric Dos, Gammon, Guy, Lesegretain, Arnaud, Mires, Derek E., Pham, Hoang, Wang, Yibin, and Khaled, Samer K.

Published
2021
Full Text
View/download PDF

15. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

Author

Gaidzik, Verena I., primary, Paschka, Peter, additional, Schlenk, Richard F., additional, Weber, Daniela, additional, Fröhling, Stefan, additional, Krämer, Alwin, additional, Wäsch, Ralph, additional, Westermann, Jörg, additional, Mayer, Karin, additional, de Wit, Maike, additional, Fiedler, Walter, additional, Benner, Axel, additional, Heuser, Michael, additional, Thol, Felicitas, additional, Döhner, Konstanze, additional, Ganser, Arnold, additional, and Döhner, Hartmut, additional

Published
2023
Full Text
View/download PDF

16. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

Author

Bochtler, Tilmann, Granzow, Martin, Stölzel, Friedrich, Kunz, Christina, Mohr, Brigitte, Kartal-Kaess, Mutlu, Hinderhofer, Katrin, Heilig, Christoph E., Kramer, Michael, Thiede, Christian, Endris, Volker, Kirchner, Martina, Stenzinger, Albrecht, Benner, Axel, Bornhäuser, Martin, Ehninger, Gerhard, Ho, Anthony D., Jauch, Anna, and Krämer, Alwin

Published
2017
Full Text
View/download PDF

17. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial

Author

Ruhnke, Leo, primary, Röllig, Christoph, additional, Herold, Sylvia, additional, Sauer, Tim, additional, Brandts, Christian H, additional, Steffen, Björn, additional, Schäfer-Eckart, Kerstin, additional, Krause, Stefan W, additional, Hänel, Mathias, additional, Reichle, Albrecht, additional, Scholl, Sebastian, additional, Neubauer, Andreas, additional, Mikesch, Jan-Henrik, additional, Schetelig, Johannes, additional, Stölzel, Friedrich, additional, Kramer, Michael, additional, Haake, Annett, additional, Frimmel, Julia, additional, Krämer, Alwin, additional, Schlenk, Richard, additional, Platzbecker, Uwe, additional, Serve, Hubert, additional, Baldus, Claudia D, additional, Müller-Tidow, Carsten, additional, Aust, Daniela, additional, Bornhäuser, Martin, additional, Ehninger, Gerhard, additional, and Thiede, Christian, additional

Published
2023
Full Text
View/download PDF

18. Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution

Author

Leppä, Aino-Maija, primary, Grimes, Karen, additional, Jeong, Hyobin, additional, Boch, Tobias, additional, Karpova, Darja, additional, Grünschläger, Florian, additional, Jauch, Anna, additional, Dolnik, Anna, additional, Rodriguez-Martin, Bernardo, additional, Bullinger, Lars, additional, Krämer, Alwin, additional, Sanders, Ashley D, additional, Korbel, Jan O, additional, and Trumpp, Andreas, additional

Published
2022
Full Text
View/download PDF

19. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41

Author

Brown, Anna L., primary, Homan, Claire, additional, Drazer, Michael W., additional, Yu, Kai, additional, Lawrence, David, additional, Feng, Jinghua, additional, Arriola-Martinez, Luis, additional, Pozsgai, Matthew, additional, McNeely, Kelsey, additional, Ha, Thuong, additional, Venugopal, Parvathy, additional, Arts, Peer, additional, King-Smith, Sarah, additional, Cheah, Jesse JC, additional, Armstrong, Mark, additional, Bödör, Csaba, additional, Wang, Paul, additional, Cantor, Alan B., additional, Cazzola, Mario, additional, Degelman, Erin, additional, DiNardo, Courtney D., additional, Duployez, Nicolas, additional, Favier, Remi, additional, Fröhling, Stefan, additional, Rio-Machin, Ana, additional, Klco, Jeffery M., additional, Krämer, Alwin, additional, Kurokawa, Mineo, additional, Lee, Joanne, additional, Malcovati, Luca, additional, Morgan, Neil V, additional, Natsoulis, Georges, additional, Owen, Carolyn, additional, Patel, Keyur P., additional, Preudhomme, Claude, additional, Raslova, Hana, additional, Rienhoff, Hugh Young, additional, Ripperger, Tim, additional, Schulte, Rachael, additional, Tawana, Kiran, additional, Velloso, Elvira Deolinda Rodrigues Pereira, additional, Yan, Benedict, additional, Sood, Raman, additional, Hsu, Amy, additional, Holland, Steven M., additional, Phillips, Kerry, additional, Poplawski, Nicola, additional, Babic, Milena, additional, Kwon Kim, Erika M, additional, Wei, Andrew H., additional, Forsyth, Cecily, additional, Mar Fan, Helen, additional, Lewis, Ian D, additional, Cooney, Julian, additional, Susman, Rachel, additional, Fox, Lucy C, additional, Blombery, Piers, additional, Singhal, Deepak, additional, Hiwase, Devendra, additional, Schreiber, Andreas W, additional, Hahn, Christopher N, additional, Scott, Hamish S, additional, Liu, Paul P., additional, and Godley, Lucy A., additional

Published
2022
Full Text
View/download PDF

20. A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma

Author

Dittrich, Tobias, primary, Köhrer, Sebastian, additional, Schorb, Martin, additional, Haberbosch, Isabella, additional, Börmel, Mandy, additional, Goldschmidt, Hartmut, additional, Pajor, Gabor, additional, Müller-Tidow, Carsten, additional, Raab, Marc S., additional, Hegenbart, Ute, additional, Schönland, Stefan O., additional, Schwab, Yannick, additional, and Krämer, Alwin, additional

Published
2022
Full Text
View/download PDF

21. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Author

Döhner, Hartmut, Lübbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver G., Müller-Tidow, Carsten, Krämer, Alwin, Raffoux, Emmanuel, Döhner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger, and Maertens, Johan

Published
2014
Full Text
View/download PDF

23. Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice

Author

Mileshkin, Linda, primary, Bochtler, Tilmann, additional, Gatta, Gemma, additional, Kurzrock, Razelle, additional, Beringer, Andreas, additional, Müller-Ohldach, Mathis, additional, Surinach, Andy, additional, Perret, Camille, additional, Thomas, Marlene, additional, Gondos, Adam, additional, and Krämer, Alwin, additional

Published
2022
Full Text
View/download PDF

24. Additional file 1 of Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Author

Eckardt, Jan-Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Abstract

Additional file 1: Impact of continuous variables on odds of EM manifestation and multivariable analysis for outcome.

Published
2022
Full Text
View/download PDF

25. Additional file 1 of Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Author

Kunadt, Desiree, Stasik, Sebastian, Metzeler, Klaus H., Röllig, Christoph, Schliemann, Christoph, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Scholl, Sebastian, Hilgendorf, Inken, Brümmendorf, Tim H., Jost, Edgar, Steffen, Björn, Bug, Gesine, Einsele, Hermann, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Wörmann, Bernhard, Kramer, Michael, Sockel, Katja, Egger-Heidrich, Katharina, Herold, Tobias, Ehninger, Gerhard, Burchert, Andreas, Platzbecker, Uwe, Berdel, Wolfgang E., Müller-Tidow, Carsten, Hiddemann, Wolfgang, Serve, Hubert, Stelljes, Matthias, Baldus, Claudia D., Neubauer, Andreas, Schetelig, Johannes, Thiede, Christian, Bornhäuser, Martin, Middeke, Jan M., and Stölzel, Friedrich

Abstract

Additional file 1: Table S1 Overview of the clinical trials the study patients were selected from. Figure S1 Forrest Plot of variables evaluated in univariate analysis. Multivariate Cox proportional hazard regression for (A) overall survival and (B) relapse-free survival.

Published
2022
Full Text
View/download PDF

27. Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders

Author

Köhrer, Sebastian, primary, Dittrich, Tobias, additional, Schorb, Martin, additional, Weinhold, Niels, additional, Haberbosch, Isabella, additional, Börmel, Mandy, additional, Pajor, Gabor, additional, Goldschmidt, Hartmut, additional, Müller-Tidow, Carsten, additional, Raab, Marc-Steffen, additional, Brobeil, Alexander, additional, Dreger, Peter, additional, Hegenbart, Ute, additional, Schönland, Stefan, additional, Schwab, Yannick, additional, and Krämer, Alwin, additional

Published
2021
Full Text
View/download PDF

28. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Author

Pauli, Chantal, Bochtler, Tilmann, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Ross, Jeffrey S, Pentheroudakis, George, Zarkavelis, George, Yalcin, Suayib, Özgüroğlu, Mustafa, Beringer, Andreas, Scarato, Jeremy, Mueller-Ohldach, Mathis, Thomas, Marlene, Moch, Holger, Krämer, Alwin, University of Zurich, and Pauli, Chantal

Subjects
10049 Institute of Pathology and Molecular Pathology, 610 Medicine & health, 2730 Oncology, 1306 Cancer Research
Published
2021

29. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy

Author

Homan, Claire C., primary, King-Smith, Sarah L., additional, Lawrence, David M., additional, Arts, Peer, additional, Feng, Jinghua, additional, Andrews, James, additional, Armstrong, Mark, additional, Ha, Thuong, additional, Dobbins, Julia, additional, Drazer, Michael W., additional, Yu, Kai, additional, Bödör, Csaba, additional, Cantor, Alan, additional, Cazzola, Mario, additional, Degelman, Erin, additional, DiNardo, Courtney D., additional, Duployez, Nicolas, additional, Favier, Remi, additional, Fröhling, Stefan, additional, Fitzgibbon, Jude, additional, Klco, Jeffery M., additional, Krämer, Alwin, additional, Kurokawa, Mineo, additional, Lee, Joanne, additional, Malcovati, Luca, additional, Morgan, Neil V., additional, Natsoulis, Georges, additional, Owen, Carolyn, additional, Patel, Keyur P., additional, Preudhomme, Claude, additional, Raslova, Hana, additional, Rienhoff, Hugh, additional, Ripperger, Tim, additional, Schulte, Rachael, additional, Tawana, Kiran, additional, Velloso, Elvira, additional, Yan, Benedict, additional, Liu, Paul, additional, Godley, Lucy A., additional, Schreiber, Andreas W., additional, Hahn, Christopher N., additional, Scott, Hamish S., additional, and Brown, Anna L., additional

Published
2021
Full Text
View/download PDF

30. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

Author

Hose, Dirk, Rème, Thierry, Meissner, Tobias, Moreaux, Jérôme, Seckinger, Anja, Lewis, Joe, Benes, Vladimir, Benner, Axel, Hundemer, Michael, Hielscher, Thomas, Shaughnessy, John D., Jr, Barlogie, Bart, Neben, Kai, Krämer, Alwin, Hillengass, Jens, Bertsch, Uta, Jauch, Anna, De Vos, John, Rossi, Jean-François, Möhler, Thomas, Blake, Jonathon, Zimmermann, Jürgen, Klein, Bernard, and Goldschmidt, Hartmut

Published
2009
Full Text
View/download PDF

31. Loss-of-function mutations of bcor are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia

Author

Eckardt, Jan-Niklas, Stasik, Sebastian, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiří, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Stölzel, Friedrich, Kroschinsky, Frank, Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Subjects
Medizin, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, risk stratification, acute myeloid leukemia, BCOR, survival, Article, loss-of-function, hemic and lymphatic diseases, ddc:610, BCORL1, RC254-282
Abstract

Cancers 13(9), 2095 (2021). doi:10.3390/cancers13092095, Published by MDPI, Basel

Published
2021

32. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

Author

Kayser, Sabine, primary, Schlenk, Richard F., additional, Lebon, Delphine, additional, Carre, Martin, additional, Götze, Katharina S., additional, Stölzel, Friedrich, additional, Berceanu, Ana, additional, Schäfer-Eckart, Kerstin, additional, Peterlin, Pierre, additional, Hicheri, Yosr, additional, Rahme, Ramy, additional, Raffoux, Emmanuel, additional, Chermat, Fatiha, additional, Krause, Stefan W., additional, Aulitzky, Walter E., additional, Rigaudeau, Sophie, additional, Noppeney, Richard, additional, Berthon, Celine, additional, Görner, Martin, additional, Jost, Edgar, additional, Carassou, Philippe, additional, Keller, Ulrich, additional, Orvain, Corentin, additional, Braun, Thorsten, additional, Saillard, Colombe, additional, Arar, Ali, additional, Kunzmann, Volker, additional, Wemeau, Mathieu, additional, De Wit, Maike, additional, Niemann, Dirk, additional, Bonmati, Caroline, additional, Schwänen, Carsten, additional, Abraham, Julie, additional, Aljijakli, Ahmad, additional, Haiat, Stephanie, additional, Krämer, Alwin, additional, Reichle, Albrecht, additional, Gnadler, Martina, additional, Willekens, Christophe, additional, Spiekermann, Karsten, additional, Hiddemann, Wolfgang, additional, Müller-Tidow, Carsten, additional, Thiede, Christian, additional, Röllig, Christoph, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Baldus, Claudia D., additional, Lengfelder, Eva, additional, Fenaux, Pierre, additional, Platzbecker, Uwe, additional, and Adès, Lionel, additional

Published
2021
Full Text
View/download PDF

33. Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Author

Eckardt, Jan-Niklas, primary, Stasik, Sebastian, additional, Kramer, Michael, additional, Röllig, Christoph, additional, Krämer, Alwin, additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Crysandt, Martina, additional, Brümmendorf, Tim H., additional, Naumann, Ralph, additional, Steffen, Björn, additional, Kunzmann, Volker, additional, Einsele, Hermann, additional, Schaich, Markus, additional, Burchert, Andreas, additional, Neubauer, Andreas, additional, Schäfer-Eckart, Kerstin, additional, Schliemann, Christoph, additional, Krause, Stefan W., additional, Herbst, Regina, additional, Hänel, Mathias, additional, Frickhofen, Norbert, additional, Noppeney, Richard, additional, Kaiser, Ulrich, additional, Baldus, Claudia D., additional, Kaufmann, Martin, additional, Rácil, Zdenek, additional, Platzbecker, Uwe, additional, Berdel, Wolfgang E., additional, Mayer, Jiří, additional, Serve, Hubert, additional, Müller-Tidow, Carsten, additional, Ehninger, Gerhard, additional, Stölzel, Friedrich, additional, Kroschinsky, Frank, additional, Schetelig, Johannes, additional, Bornhäuser, Martin, additional, Thiede, Christian, additional, and Middeke, Jan Moritz, additional

Published
2021
Full Text
View/download PDF

34. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Author

Röllig, Christoph, Steffen, Björn, Alakel, Nael, Herbst, Regina, Noppeney, Richard, Hanoun, Maher, Racil, Zdenek, Schäfer-Eckart, Kerstin, Krämer, Alwin, Neubauer, Andreas, Baldus, Claudia D, Schliemann, Christoph, Kaufmann, Martin, Mertova, Jolana, Jost, Edgar, Niemann, Dirk, Novak, Jan, Krause, Stefan W, Scholl, Sebastian, Held, Gerhard, Parmentier, Stefani B., Szotkowski, Tomáš, Zak, Pavel, Rank, Andreas, Wass, Maxi, Buske, Sebastian, Kramer, Michael, Fiebig, Frank, Haake, Annett, Schetelig, Johannes, Platzbecker, Uwe, Thiede, Christian, Müller-Tidow, Carsten, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Mayer, Jiri, and Bornhäuser, Martin

Published
2020
Full Text
View/download PDF

35. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study

Author

Kayser, Sabine, Schlenk, Richard F., Lebon, Delphine, Carre, Martin, Götze, Katharina S., Stölzel, Friedrich, Berceanu, Ana, Schäfer-Eckart, Kerstin, Peterlin, Pierre, Hicheri, Yosr, Rahme, Ramy, Raffoux, Emmanuel, Chermat, Fatiha, Krause, Stefan W., Aulitzky, Walter E., Rigaudeau, Sophie, Noppeney, Richard, Berthon, Celine, Görner, Martin, Jost, Edgar, Carassou, Philippe, Keller, Ulrich, Orvain, Corentin, Braun, Thorsten, Saillard, Colombe, Arar, Ali, Kunzmann, Volker, Wemeau, Mathieu, De Wit, Maike, Niemann, Dirk, Bonmati, Caroline, Schwänen, Carsten, Abraham, Julie, Aljijakli, Ahmad, Haiat, Stephanie, Krämer, Alwin, Reichle, Albrecht, Gnadler, Martina, Willekens, Christophe, Spiekermann, Karsten, Hiddemann, Wolfgang, Müller-Tidow, Carsten, Thiede, Christian, Röllig, Christoph, Serve, Hubert, Bornhäuser, Martin, Baldus, Claudia D., Lengfelder, Eva, Fenaux, Pierre, Platzbecker, Uwe, and Adès, Lionel

Subjects
ddc
Published
2020

36. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2and DDX41

Author

Brown, Anna L., Homan, Claire, Drazer, Michael W., Yu, Kai, Lawrence, David, Feng, Jinghua, Arriola-Martinez, Luis, Pozsgai, Matthew, McNeely, Kelsey, Ha, Thuong, Venugopal, Parvathy, Arts, Peer, King-Smith, Sarah, Cheah, Jesse JC, Armstrong, Mark, Bödör, Csaba, Wang, Paul, Cantor, Alan B., Cazzola, Mario, Degelman, Erin, DiNardo, Courtney D., Duployez, Nicolas, Favier, Remi, Fröhling, Stefan, Rio-Machin, Ana, Klco, Jeffery M., Krämer, Alwin, Kurokawa, Mineo, Lee, Joanne, Malcovati, Luca, Morgan, Neil V, Natsoulis, Georges, Owen, Carolyn, Patel, Keyur P., Preudhomme, Claude, Raslova, Hana, Rienhoff, Hugh Young, Ripperger, Tim, Schulte, Rachael, Tawana, Kiran, Velloso, Elvira Deolinda Rodrigues Pereira, Yan, Benedict, Sood, Raman, Hsu, Amy, Holland, Steven M., Phillips, Kerry, Poplawski, Nicola, Babic, Milena, Kwon Kim, Erika M, Wei, Andrew H., Forsyth, Cecily, Mar Fan, Helen, Lewis, Ian D, Cooney, Julian, Susman, Rachel, Fox, Lucy C, Blombery, Piers, Singhal, Deepak, Hiwase, Devendra, Schreiber, Andreas W, Hahn, Christopher N, Scott, Hamish S, Liu, Paul P., and Godley, Lucy A.

Published
2022
Full Text
View/download PDF

37. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Author

Pauli, Chantal, primary, Bochtler, Tilmann, additional, Mileshkin, Linda, additional, Baciarello, Giulia, additional, Losa, Ferran, additional, Ross, Jeffrey S., additional, Pentheroudakis, George, additional, Zarkavelis, George, additional, Yalcin, Suayib, additional, Özgüroğlu, Mustafa, additional, Beringer, Andreas, additional, Scarato, Jeremy, additional, Mueller-Ohldach, Mathis, additional, Thomas, Marlene, additional, Moch, Holger, additional, and Krämer, Alwin, additional

Published
2021
Full Text
View/download PDF

38. HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells

Author

Figueroa-Vazquez, Vianihuini, primary, Ko, Jonathan, additional, Breunig, Christian, additional, Baumann, Anja, additional, Giesen, Nicola, additional, Pálfi, Anikó, additional, Müller, Christoph, additional, Lutz, Christian, additional, Hechler, Torsten, additional, Kulke, Michael, additional, Müller-Tidow, Carsten, additional, Krämer, Alwin, additional, Goldschmidt, Hartmut, additional, Pahl, Andreas, additional, and Raab, Marc S., additional

Published
2021
Full Text
View/download PDF

40. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design

Author

Ross, Jeffrey S., primary, Sokol, Ethan S., additional, Moch, Holger, additional, Mileshkin, Linda, additional, Baciarello, Giulia, additional, Losa, Ferran, additional, Beringer, Andreas, additional, Thomas, Marlene, additional, Elvin, Julia A., additional, Ngo, Nhu, additional, Jin, Dexter X., additional, and Krämer, Alwin, additional

Published
2020
Full Text
View/download PDF

41. Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Author

Kayser, Sabine, primary, Middeke, Jan Moritz, additional, Kramer, Michael, additional, Sockel, Katja, additional, Stasik, Sebastian, additional, Herbst, Regina, additional, Fransecky, Lars R., additional, Wolf, Dominik, additional, Martin, Schumacher, additional, Krämer, Alwin, additional, Noppeney, Richard, additional, Novotny, Juergen, additional, Bug, Gesine, additional, Götze, Katharina S., additional, Spiekermann, Karsten, additional, Stelljes, Matthias, additional, Mikesch, Jan-Henrik, additional, Subklewe, Marion, additional, Schubert, Antje, additional, Mütherig, Anke, additional, Bochtler, Tilmann, additional, Mende, Marika, additional, Stoelzel, Friedrich, additional, Kubasch, Anne, additional, Von Bonin, Malte, additional, Haenel, Mathias, additional, Duehrsen, Ulrich, additional, Schetelig, Johannes, additional, Rollig, Christoph, additional, Baldus, Claudia D, additional, Ehninger, Gerhard, additional, Müller-Tidow, Carsten, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Platzbecker, Uwe, additional, and Thiede, Christian, additional

Published
2020
Full Text
View/download PDF

43. Abstract 784: Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)

Author

Perl, Alexander E., primary, Cortes, Jorge E., additional, Ganguly, Siddhartha, additional, Khaled, Samer K., additional, Krämer, Alwin, additional, Martinelli, Giovanni, additional, Russell, Nigel H., additional, Chang, Ken C., additional, Kato, Kazunobu, additional, Yan, Yuhu, additional, Xu, Li-An, additional, Korkhov, Sergey, additional, Günnel, Tobias, additional, Sumi, Hiroyuki, additional, Lesegretain, Arnaud, additional, Berisha, Flora, additional, Mires, Derek, additional, Benzohra, Aziz, additional, Isoyama, Takeshi, additional, Santos, Cedric Dos, additional, and Levis, Mark J., additional

Published
2020
Full Text
View/download PDF

44. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Author

Röllig, Christoph, primary, Kramer, Michael, additional, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Steffen, Björn, additional, Krämer, Alwin, additional, Noppeney, Richard, additional, Schäfer-Eckart, Kerstin, additional, Krause, Stefan W., additional, Hänel, Mathias, additional, Herbst, Regina, additional, Kunzmann, Volker, additional, Einsele, Hermann, additional, Jost, Edgar, additional, Brümmendorf, Tim H., additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Neubauer, Andreas, additional, Sohlbach, Kristina, additional, Fransecky, Lars, additional, Kaufmann, Martin, additional, Niemann, Dirk, additional, Schaich, Markus, additional, Frickhofen, Norbert, additional, Kiani, Alexander, additional, Heits, Frank, additional, Krümpelmann, Ulrich, additional, Kaiser, Ulrich, additional, Kullmer, Johannes, additional, Wass, Maxi, additional, Stölzel, Friedrich, additional, von Bonin, Malte, additional, Middeke, Jan Moritz, additional, Thiede, Christian, additional, Schetelig, Johannes, additional, Berdel, Wolfgang E., additional, Ehninger, Gerhard, additional, Baldus, Claudia D., additional, Müller-Tidow, Carsten, additional, Platzbecker, Uwe, additional, Serve, Hubert, additional, and Bornhäuser, Martin, additional

Published
2020
Full Text
View/download PDF

45. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Author

Brown, Anna L., primary, Arts, Peer, primary, Carmichael, Catherine L., primary, Babic, Milena, primary, Dobbins, Julia, primary, Chong, Chan-Eng, primary, Schreiber, Andreas W., primary, Feng, Jinghua, primary, Phillips, Kerry, primary, Wang, Paul P. S., primary, Ha, Thuong, primary, Homan, Claire C., primary, King-Smith, Sarah L., primary, Rawlings, Lesley, primary, Vakulin, Cassandra, primary, Dubowsky, Andrew, primary, Burdett, Jessica, primary, Moore, Sarah, primary, McKavanagh, Grace, primary, Henry, Denae, primary, Wells, Amanda, primary, Mercorella, Belinda, primary, Nicola, Mario, primary, Suttle, Jeffrey, primary, Wilkins, Ella, primary, Li, Xiao-Chun, primary, Michaud, Joelle, primary, Brautigan, Peter, primary, Cannon, Ping, primary, Altree, Meryl, primary, Jaensch, Louise, primary, Fine, Miriam, primary, Butcher, Carolyn, primary, D’Andrea, Richard J., primary, Lewis, Ian D., primary, Hiwase, Devendra K., primary, Papaemmanuil, Elli, primary, Horwitz, Marshall S., primary, Natsoulis, Georges, primary, Rienhoff, Hugh Y., primary, Patton, Nigel, primary, Mapp, Sally, primary, Susman, Rachel, primary, Morgan, Susan, primary, Cooney, Julian, primary, Currie, Mark, primary, Popat, Uday, primary, Bochtler, Tilmann, primary, Izraeli, Shai, primary, Bradstock, Kenneth, primary, Godley, Lucy A., primary, Krämer, Alwin, primary, Fröhling, Stefan, primary, Wei, Andrew H., primary, Forsyth, Cecily, primary, Mar Fan, Helen, primary, Poplawski, Nicola K., primary, Hahn, Christopher N., primary, and Scott, Hamish S., primary

Published
2020
Full Text
View/download PDF

46. Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Author

Ganguly, Siddhartha, primary, Cortes, Jorge E., additional, Krämer, Alwin, additional, Levis, Mark J., additional, Martinelli, Giovanni, additional, Perl, Alexander E., additional, Russell, Nigel H., additional, Arunachalam, Meena, additional, Gammon, Guy, additional, Lesegretain, Arnaud, additional, Mires, Derek E., additional, and Khaled, Samer K., additional

Published
2020
Full Text
View/download PDF

47. Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Author

Röllig, Christoph, primary, Kramer, Michael, primary, Schliemann, Christoph, primary, Mikesch, Jan-Henrik, primary, Steffen, Björn, primary, Krämer, Alwin, primary, Sauer, Tim, primary, Hänel, Mathias, primary, Herbst, Regina, primary, Schäfer-Eckart, Kerstin, primary, Noppeney, Richard, primary, Jost, Edgar, primary, Brümmendorf, Tim H, primary, Krause, Stefan W, primary, Kunzmann, Volker, primary, Einsele, Hermann, primary, Scholl, Sebastian, primary, Hochhaus, Andreas, primary, Fransecky, Lars R., primary, Kaufmann, Martin, primary, Neubauer, Andreas, primary, Niemann, Dirk, primary, Schaich, Markus, primary, Frickhofen, Norbert, primary, Kiani, Alexander, primary, Heits, Frank, primary, Krümpelmann, Ulrich, primary, Kaiser, Ulrich, primary, Kullmer, Johannes, primary, Wass, Maxi, primary, Klein, Stefan, primary, Von Bonin, Malte, primary, Middeke, Jan Moritz, primary, Thiede, Christian, primary, Stoelzel, Friedrich, primary, Schetelig, Johannes, primary, Ehninger, Gerhard, primary, Baldus, Claudia D, primary, Müller-Tidow, Carsten, primary, Platzbecker, Uwe, primary, Serve, Hubert, primary, and Bornhäuser, Martin, primary

Published
2019
Full Text
View/download PDF

48. Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Author

Cortes, Jorge E., primary, Ganguly, Siddhartha, additional, Krämer, Alwin, additional, Levis, Mark J., additional, Martinelli, Giovanni, additional, Perl, Alexander E., additional, Russell, Nigel H., additional, Choi, Youngsook, additional, Mendell, Jeanne, additional, Namuyinga, Ruth, additional, Pham, Hoang, additional, Said, Nabil, additional, Wang, Yibin, additional, Mitov, Tsvetomir, additional, Kim, Ben, additional, and Khaled, Samer K., additional

Published
2019
Full Text
View/download PDF

49. Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Author

Perl, Alexander E., primary, Cortes, Jorge E., primary, Ganguly, Siddhartha, primary, Khaled, Samer K., primary, Krämer, Alwin, primary, Martinelli, Giovanni, primary, Russell, Nigel H., primary, Chang, Ken CN, primary, Mires, Derek E., primary, Kato, Kazunobu, primary, Zhang, Yufen, primary, Korkhov, Sergey, primary, Wang, Zhenyu, primary, Günnel, Tobias, primary, Sumi, Hiroyuki, primary, Isoyama, Takeshi, primary, Lesegretain, Arnaud, primary, Berisha, Flora, primary, Dos Santos, Cedric E., primary, and Levis, Mark J., primary

Published
2019
Full Text
View/download PDF

50. Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Author

Ganguly, Siddhartha, primary, Cortes, Jorge E., primary, Krämer, Alwin, primary, Levis, Mark J., primary, Martinelli, Giovanni, primary, Perl, Alexander E., primary, Russell, Nigel H., primary, Arunachalam, Meena, primary, Gammon, Guy, primary, Lesegretain, Arnaud, primary, Mires, Derek E., primary, Namuyinga, Ruth, primary, Zhang, Yufen, primary, and Khaled, Samer K., primary

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results